Anavex Life Sciences Corp (AVXL)

[rocalinda]

"Why no enrollment update for the 20 patient Rett trial? What is taking so long and why is the company not updating?"

From this morning cinical update:

To offer all participants access to ANAVEX®2-73 (blarcamesine) after completion of the ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett syndrome study1 and the AVATAR Rett syndrome study2, 12-week and 48-week open-label extension studies, respectively were initiated. Currently 90% and 100% of eligible participants have continued into the corresponding extension studies.
The international EXCELLENCE Rett syndrome study of ANAVEX®2-73 (blarcamesine) in pediatric patients was approved by the Australian Human Research Ethics Committee and is scheduled to initiate early 2020.

Hopefully more clarity this afternoon.